Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2013 Dec;94(6):640-5.
doi: 10.1038/clpt.2013.172. Epub 2013 Aug 29.

Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing

K E Caudle  1 , C F Thorn, T E Klein, J J Swen, H L McLeod, R B Diasio, M Schwab
Affiliations
Practice Guideline

Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing

K E Caudle et al. Clin Pharmacol Ther. 2013 Dec.

Abstract

The fluoropyrimidines are the mainstay chemotherapeutic agents for the treatment of many types of cancers. Detoxifying metabolism of fluoropyrimidines requires dihydropyrimidine dehydrogenase (DPD, encoded by the DPYD gene), and reduced or absent activity of this enzyme can result in severe, and sometimes fatal, toxicity. We summarize evidence from the published literature supporting this association and provide dosing recommendations for fluoropyrimidines based on DPYD genotype (updates at http://www.pharmgkb.org).

PubMed Disclaimer

References

    1. Diasio R.B., Harris B.E. Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet. 1989;16:215–237. - PubMed
    1. Relling M.V., Klein T.E. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin. Pharmacol. Ther. 2011;89:464–467. - PMC - PubMed
    1. Thorn C.F., Marsh S., Carrillo M.W., McLeod H.L., Klein T.E., Altman R.B. PharmGKB summary: fluoropyrimidine pathways. Pharmacogenet. Genomics. 2011;21:237–242. - PMC - PubMed
    1. Fleming R.A., et al. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res. 1992;52:2899–2902. - PubMed
    1. Johnson M.R., Wang K., Diasio R.B. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin. Cancer Res. 2002;8:768–774. - PubMed

Publication types

MeSH terms